Europe Allogeneic Human Chondrocyte Market Driven By High Prevalence of Musculoskeletal Injuries in Europe
Allogeneic human chondrocyte is an emerging therapy that can be used for cartilage repair and other indications. It finds application in the treatment of musculoskeletal disorders and cartilage defects. It helps to reduce the risk of host-immune rejection due to its autologous nature and facilitates direct restoration of hyaline cartilage. Moreover, the therapy is less invasive and offers shorter recovery times compared to alternative, comparable therapies. The Europe allogeneic human chondrocyte market is expected to witness significant growth, owing to high prevalence of musculoskeletal injuries in the region. According to the Study, ‘Prevalence of Musculoskeletal Injuries, Pain, and Illnesses in Elite Female Basketball Players, in Europe, in June 2019, the most frequently injured body parts were lower limbs: more than 60%, representing an injury rate of 0.14 per athletes and a 0.2 pain rate per athlete (during the study period). Allogeneic human chondrocyte can be used in...